Close Menu

Breaking News

CEO Prahlad Singh said the firm is developing a PCR- and antibody-based assay for the novel coronavirus 2019-nCoV and is working with the Chinese NMPA.

The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.

The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.

The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.

The agency plans to make test kits available to state and international partners in the next two weeks. It also provided updated information about the virus.

The study, led by researchers from precision health firm Human Longevity, also uncovered phenotypic evidence supporting some pathogenic genetic findings.

Nine of the genes analyzed had limited or disputed evidence linking them to long QT syndrome, suggesting they should not be included in genetic testing panels.

Natera alleged that certain cell-free DNA-based oncology products sold by Archer Dx infringe its US Patent 10,538,814, which was issued earlier this month.

The new center will bring together pathology, computer science, cancer genomics, and immunogenomics to study which cancer patients can benefit from immunotherapy.

The company said it has started the CE mark approval process of commissioned high-risk HPV genotyping assays and expects to certify them this year.

Last week, GenomeWeb's readers were most interested in 23andMe laying off approximately 100 employees, about 14 percent of its workforce.

The partners will use Noscendo's Disqver next-generation sequencing-based diagnostic platform to characterize antibiotic-resistant pathogens.

Quantitative Medicine has developed a computational drug discovery platform, called Core, that can predict the main effects of drugs on disease-associated targets.

News items for the week of Jan. 20, 2020.

A federal judge granted IonPath's motion to dismiss portions of Fluidigm's suit but claims of direct infringement were untouched and will proceed.

Researchers from UBC, the BC Centre for Disease Control, and elsewhere will conduct a multi-omics study of the foodborne pathogen.

The panels will select candidate genes that will have a high impact on clinical practice in areas of high priority for participating institutes and centers.

The company, which is developing an assay for the 2019-nCoV coronavirus, is offering about 3.5 million shares of its common stock at $1.45 per share.

The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.

The layoffs occurred across 23andMe's consumer business, which is being restructured, but did not impact its therapeutics business.

QCMD said it will use the technology to develop new reagents for use with its own molecular infectious disease proficiency testing solutions.

Exome sequences for nearly 35,600 cases and controls revealed genes prone to mutation in autism spectrum disorder, along with related cell types, functions, and developmental stages.

The Medical Genome Reference Bank, which currently holds data for more than 2,500 healthy elderly Australians, could help scientists understand the genetics of healthy aging.

Pages

Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.

ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.

The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.

In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.